Imlygic (talimogene laherparepvec) / Amgen 
Welcome,         Profile    Billing    Logout  
 23 Diseases   21 Trials   21 Trials   1236 News 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imlygic (talimogene laherparepvec) / Amgen
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

No Longer Available
3b
US
Talimogene Laherparepvec
Amgen
Unresected Stage IIIb to IVM1c Melanoma
 
 
NCT02297529 / 2014-002834-30: Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

No Longer Available
3b
Europe
Talimogene Laherparepvec
Amgen
Unresected Stage IIIB to IVM1c Melanoma
 
 
2016-000317-78: Comparison of PV-10 to Chemotherapy or Oncolytic Viral Therapy for Treatment of Malignant Melanoma of the Skin Confronto tra PV-10 verso chemioterapia o terapia virale oncolitica per il trattamento del melanoma cutaneo localmente avanzato

Not yet recruiting
3
225
Europe
PV-10, Temozolomide, Dacarbazine, Temodal 20 mg capsule rigide, Temodal 100 mg capsule rigide, Temozolamide, TEMODAL, NA, Suspension for injection, Powder for solution for injection, Capsule, hard, Solution for injection, DACARBAZINA MEDAC - 200 MG POLVERE PER SOLUZIONE INIETTABILE O PER INFUSIONE 10 FLACONCINI IN VETRO, Temodal 5 mg capsule rigide, Imlygic 10^6 plaque forming units (PFU)/mL solution for injection, DACARBAZINA MEDAC - 500 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO, TEMODAL - 20 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 20 CAPSULE, TEMODAL - 100 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, TEMODAL - 140 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, TEMODAL - 180 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 20 CAPSULE, TEMODAL - 250 MG - CAPSULA RIGIDA- USO ORALE- CAPSULE IN BUSTINE SIGILLATE INDIVIDUALMENTE 5 CAPSULE, Imlygic 10^8 plaque forming units (PFU)/mL solution for injection
PROVECTUS BIOPHARMACEUTICALS, INC., Provectus Biopharmaceuticals, Inc
Locally Advanced Cutaneous Melanoma Melanoma cutaneo localmente avanzato, Malignant melanoma of skin Melanoma maligno della pelle, Diseases [C] - Cancer [C04]
 
 
2018-002165-19: Reduction of the size of a wide spread white skin cancer with an oncolytic virus before surgery

Ongoing
2
40
Europe
Talimogene laherparepvec (Imlygic), Solution for injection, Imlygic Talimogene Laherparepvec
Medical University Vienna, Amgen
Basal cell carcinoma (BCC) is the most common malignant neoplasm in fair skinned humans (Rubin et al., 2005). Over the last decades its incidence has increased (Chinem and Miot, 2011). Especially when it comes to BCCs of intermediate size, a surgical approach, while still feasible is often associated with complications and often requires major reconstructive surgery with a suboptimal cosmetic outcome. We hypothesize that neoadjuvant Talimogene laherparepvec minimizes the size of the BCC., White skin cancer is a very common disease. Wide spread white skin cancer is difficult to treat. We hypothesize that the size of the tumor reduces through oncolytic virotherapy before surgery., Diseases [C] - Cancer [C04]
 
 
2018-002677-22: Doppler sonography (non-invasive test that calculates blood flow in blood vessels) of skin and nodal metastases (cancer spread from the skin, where it was originally formed, to the nodal tissue) as a predictor of clinical response to Talimogene Laherparepvec (T-VEC), biopharmaceutical drug to treat melanoma lesions that can not be operated, in melanoma patients (T-VEC – US Doppler) Ecografía Doppler (prueba no invasiva que calcula el flujo de la sangre en los vasos sanguíneos) de piel y metástasis ganglionares (diseminación del cáncer desde la piel, donde se formó originalmente, al tejido ganglionar) como predictor de la respuesta clínica a Talimogene Laherparepvec (T-VEC), medicamento biofarmacéutico para tratar lesiones de melanoma que no pueden operarse, en pacientes con melanoma (T-VEC - US Doppler)

Not yet recruiting
2
25
Europe
Talimogene Laherparepvec, AMG 678, Solution for solution for injection, IMLYGIC
Fundació Clínic per a la Recerca Biomèdica, AMGEN S.A.
Melanoma stage IIIB-IVM1a Melanoma estadío IIIB-IVM1a, Melanoma (most serious type of skin cancer) in stage IIIB (cancer present in skin cells and in lymphatic ganglia) to IVM1a (cutaneous metastases, subcutaneous and ganglionic at distance) Melanoma (cáncer de piel más grave) estadio IIIB (cáncer presente en células de la piel y en ganglios linfáticos) a IVM1a (metástasis cutáneas, subcutáneas y ganglionares a distancia, Diseases [C] - Cancer [C04]
 
 
2019-001911-22: A study in melanoma patients with metastases in the lymph nodes and/or on/under the skin who will be treated with T-VEC and nivolumab before surgery.

Not yet recruiting
2
24
Europe
Nivolumab, Talimogene Laherparepvec, AMG 678, Solution for injection/infusion, Solution for infusion, Opdivo, Imlygic
Antoni van Leeuwenhoek Ziekenhuis, Bristol Myers Squibb (BMS), Amgen
Patients with early metastatic (stage IIIB/C/D/IV M1a (AJCC 8)) melanoma Patienten met vroeg gemetastaseerd (stadium IIIB/IIIC of IVM1a) melanoom, Patients with skin cancer with metastases to the lymph nodes and/or on/under the skin Patienten met huidkanker met uitzaaiingen in de lymfeklieren en/of op/onder de huid, Diseases [C] - Cancer [C04]
 
 
2019-004403-12: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study Essai clinique de phase II multicentrique évaluant le talimogene laherparepvec dans la maladie de Kaposi classique ou endémique

Not yet recruiting
2
20
Europe
talimogene laherparepvec, Solution for injection, Imlygic
ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS, Amgen
The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS traitement par T-Vec de patients atteints du Sarcome de Kaposi., Diseases [C] - Cancer [C04]
 
 
MASTERKEY-115, NCT04068181 / 2019-001906-61: Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy () (Mk-3475-A07/KEYNOTE-A07).

Completed
2
72
Europe, Canada, US, RoW
Talimogene laherparepvec, Pembrolizumab
Amgen, Merck Sharp & Dohme LLC
Melanoma
08/21
02/24
NCT04427306: Neoadjuvant T-VEC in High Risk Early Melanoma

Suspended
2
6
US
T-Vec, talimogene laherparepvec, Amgen
University of California, Davis, Amgen
Melanoma
06/22
05/24
KAPVEC, NCT04065152: Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma

Recruiting
2
20
Europe
Talimogene laherparepvec
Assistance Publique - Hôpitaux de Paris
Kaposi Sarcoma
02/23
02/24
NIVEC, NCT04330430: Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease

Active, not recruiting
2
24
Europe
T-VEC, Nivolumab
The Netherlands Cancer Institute, Amgen
Melanoma Stage III, Melanoma Stage IV
04/23
01/25
S1607, NCT02965716: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Active, not recruiting
2
42
US
Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
06/23
11/24
NCT03714828: Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

Completed
2
11
US
Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection
University of Arizona, Amgen
Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
07/23
07/23
NCT02923778: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Active, not recruiting
2
40
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
12/24
12/24
SOC-1882, NCT03886311: Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Recruiting
2
40
US
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], TVEC, Imlygic, Nivolumab IV Soln 100 MG/10ML, Opdivo, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution, Yondelis
Sarcoma Oncology Research Center, LLC
Sarcoma
12/24
03/25
NCT03069378: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting
2
41
US
Talimogene Laherparepvec (T-VEC), Pembrolizumab
Memorial Sloan Kettering Cancer Center, Amgen, Merck Sharp & Dohme LLC
Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
03/25
03/25
NCT02819843: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Completed
2
19
US
TALIMOGENE LAHERPAREPVEC (TVEC), Hypofractionated Radiotherapy
Memorial Sloan Kettering Cancer Center, Amgen
Melanoma, Merkel Cell Carcinoma, Other Solid Tumors
02/24
02/24
NCT02978625: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Active, not recruiting
2
68
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Mammography, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Keratoacanthoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
09/25
09/25
NCT03842943: Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Recruiting
2
28
US
Pembrolizumab, Keytruda, Talimogene Laherparepvec, T-VEC, Imlygic
University of Louisville
Cutaneous Melanoma
06/26
06/28
MASTERKEY318, NCT02509507 / 2014-005386-67: Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

Completed
1b/2
127
Europe, US, RoW
Talimogene Laherparepvec, Pembrolizumab
Amgen, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
02/22
07/23
2005-000777-21: AN EXPLORATORY STUDY OF THE SAFETY AND BIOLOGICAL ACTIVITY OF ONCOVEXGM-CSF IN COMBINATION WITH RADIOTHERAPY AND CISPLATIN IN THE TREATMENT OF LOCALLY ADVANCED EPITHELIAL CANCER OF THE HEAD AND NECK

Ongoing
1/2
20
Europe
ONCOVEXGM-CSF,
BioVex Ltd
Locally advanced epithelial cancer of the head and neck.
 
 
NCT02453191: TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Completed
1/2
30
US
Talimogene Laherparepvec, Radiotherapy
University of Iowa, Amgen
Soft Tissue Sarcoma
01/19
03/23
NCT02779855: Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Active, not recruiting
1/2
50
US
Talimogene laherparepvec, IMLYGIC™, modified herpes simplex 1 virus, Paclitaxel, Taxol®
H. Lee Moffitt Cancer Center and Research Institute, Amgen
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
09/20
08/24
NCT04599062: TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Active, not recruiting
1/2
8
US
Talimogene Laherparepvec, Radiotherapy
Mohammed Milhem, Amgen
Soft Tissue Sarcoma
02/23
11/24
NCT03088176: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Active, not recruiting
1b
4
US
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Imlygic, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Tafinlar, Trametinib, Mekinist
West Cancer Center, University of Tennessee Health Science Center, Amgen
Melanoma, BRAF Gene Mutation
11/20
06/21
NCT03554044: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Active, not recruiting
1b
20
US
Anastrozole, Arimidex, ICI-D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, ICI 182,780, ZD9238, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC, OncoVEXGM-CSF, Tamoxifen, Nolvadex, Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin
University of California, San Francisco, Amgen
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
04/25
04/25
NCT03300544: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated
1
3
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
03/22
03/22
PROMETEO, NCT03802604: Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Active, not recruiting
1
28
Europe
Talimogene laherparepvec, T-VEC, Imlygic, Atezolizumab, Tecentric
SOLTI Breast Cancer Research Group, Amgen, Roche Pharma AG
Breast Cancer
04/22
04/25
Glaspy BMS CA209-9ET Breast, NCT04185311: Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated
1
6
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
05/23
05/23
myDCTV, NCT03747744: Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)

Active, not recruiting
1
18
Europe
CD1c (BDCA-1)+ myDC, intratumoral injection of talimogene laherparepvec (T-VEC)
Universitair Ziekenhuis Brussel
Melanoma
10/23
10/23
NCT03086642: Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Active, not recruiting
1
9
US
Talimogene laherparepvec, T-Vec, T Vec
Karie D. Runcie, MD, Amgen
Pancreatic Cancer
12/23
04/26
NCT04163952: Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

Active, not recruiting
1
5
US
Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
02/25
02/25
NCT02910557: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

Recruiting
N/A
300
Europe, US, RoW
Amgen
Melanoma, Herpetic Infection
08/38
08/38

Download Options